Health Care Activity – Page 11

Senator Sanders Investigates Skyrocketing Costs of Novo Nordisk’s Diabetes and Weight Loss Drugs

12 months ago talkbio0Tagged Affordability, Diabetes, Evaluation, Health care facility, Nordisk, Novos, Prices, Senator Bernie Sanders, Wegovy

Senator Bernie Sanders, Novo Nordisk, diabetes, weight loss, drug prices, Novos Ozempic, Wegovy, investigation, healthcare costs, affordability

Strategic Acquisition, Partnership, and Development of Innovative Assets in Biopharma

12 months ago talkbio0Tagged Acquisition (action), Biopharma, development aspects, Drug Development, Drug Industry, innovative assets, Market, Partnership, Portfolio diversification, Risk Management, strategic decision-making, trends qualifier

Biopharma, Innovative Assets, Acquisition, Partnership, Development, Strategic Decision-Making, Pharmaceutical Industry, Drug Development, Market Trends, Risk Management, Portfolio Diversification

Projected $270 Billion Orphan Drug Market by 2028: A Comprehensive Analysis of Leading Players J&J, Vertex, and Roche

1 year ago talkbio0Tagged Drugs, Orphan, Evaluation, Growth, J&J, Market, Roche (company)

Orphan drugs, rare diseases, J&J, Vertex, Roche, market growth, 2028, Evaluate

Life Sciences Senior Associate: Evaluating Opportunities in Therapeutics, Diagnostics, and Health Tech

1 year ago talkbio0Tagged Diagnostics, diligence, Evaluation, Life Sciences Senior Associate, research tools, Technology, Health Care

Life Sciences Senior Associate, Therapeutics, Diagnostics, Research Tools, Health Technology, Opportunity Evaluation, Diligence

EU Regulators Confirm No Link Between GLP-1 Drugs and Suicidal Thoughts

1 year ago talkbio0Tagged European Medicines Agency, Evaluation, Feeling suicidal (finding), Glucagon-Like Peptide 1, Ozempic, Wegovy

GLP-1 drugs, Ozempic, Wegovy, European Medicines Agency (EMA), No link to suicidal thoughts, Investigation

EMA Dispels Link Between GLP-1 Receptor Agonists and Suicidal Ideation Risk New

1 year ago talkbio0Tagged agonists, Continuous, Diabetes, Glucagon-Like Peptide-1 Receptor, Mental association, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, pharmacovigilance activities, Preventive monitoring, Suicidal ideation risk, Weight-Loss Agents

EMA, GLP-1 receptor agonists, Diabetes and weight-loss drugs, Suicidal ideation risk, No causal association, Pharmacovigilance activities, Continued monitoring

FDA Approves Vadadustat (Vafseo) for Anemia in Chronic Kidney Disease Patients on Dialysis and Daprodustat (Jesduvroq) for Dialysis-Dependent CKD Adults

1 year ago talkbio0Tagged Anemia, Approved, Black Box Warning, Chronic Kidney Diseases, Daprodustat, Effectiveness, Hemoglobin concentration result, Jesduvroq, Oral Medication, post-marketing safety, Safety, United States Food and Drug Administration, vadadustat, Vafseo

Anemia, Chronic Kidney Disease (CKD), Vadadustat (Vafseo), Daprodustat (Jesduvroq), Oral medication, FDA approval, Hemoglobin levels, Black Box Warning, Efficacy and safety data, Post-marketing safety data

AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation

1 year ago talkbio0Tagged AstraZeneca, Evaluation, Inhaler, Prices, SmithKline Beecham

Evaluation, Inhaler, AstraZeneca, SmithKline Beecham, Prices

Biden Proposes Expansion of Medicare Drug Price Negotiation Program

1 year ago talkbio0Tagged Bidens, drug price, Health Care, Increased, Mediation, Medicare, scrutiny

Biden, Medicare, Drug Prices, Negotiation, Increased Scrutiny, More Drugs, Health Care Policy

NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns

1 year ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Coverage rejection, Daiichi Sankyo, Enhertu, Health Services, National, Malignant neoplasm of breast, Nitroglycerin/Sodium Citrate/Ethanol Solution, Technology

NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)